Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yi-Fei San-Jie Pill maintenance therapy after first-line chemotherapy for advanced non-small-cell lung cancer
ChiCTR2000029166Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of yi-fei san-jie pill in non-small cell lung cancer (NSCLC) (2 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Progression-free survival. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
yi-fei san-jie pill
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000029166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029166.